8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): August 5, 2013

LANDAUER, INC.

(Exact Name of Registrant as Specified in Its Charter)

Delaware (State or Other Jurisdiction of Incorporation) 1-9788 (Commission File Number) 06-1218089 (IRS Employer Identification No.)

2 Science Road, Glenwood, Illinois 60425

(Address of Principal Executive Offices) (Zip Code)

Registrant’s Telephone Number, Including Area Code: (708) 755-7000

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

1

Item 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION

On August 5, 2013, Landauer, Inc. (the “Company”) issued a Press Release announcing its earnings for its fiscal 2013 third quarter ended June 30, 2013. A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Item 7.01 REGULATION FD DISCLOSURE

Beginning August 6, 2013, the Company will make available and distribute to analysts and prospective investors a slide presentation. The presentation materials include information regarding the Company’s operating and growth strategies and financial performance. Pursuant to Regulation FD, the presentation materials are attached as Exhibit 99.2 to this Current Report on Form 8-K.

Item 9.01 FINANCIAL STATEMENTS AND EXHIBITS

(d)	Exhibits.
	99.1	Press Release, dated August 5, 2013
	99.2	Investor Slide Presentation

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	LANDAUER, INC.
August 6, 2013	By:	/s/ Michael K. Burke
		Michael K. Burke
		Senior Vice President and Chief Financial Officer (Principal Financial Officer)

3

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press Release, dated August 5, 2013
99.2	Investor Slide Presentation

4

EX-99.1

Exhibit 99.1

News Release

LANDAUER

LANDAUER, INC. Reports

Fiscal 2013 third Quarter Results

For Further Information Contact:

     Jim Polson

     FTI Consulting

     Phone: 312-553-6730

     Email: jim.polson@fticonsulting.com

GLENWOOD, Ill.— August 5, 2013—Landauer, Inc. (NYSE: LDR), a recognized leader in personal and environmental radiation measurement and monitoring, outsourced medical physics services andhigh quality medical consumable accessories, today reported financial results for its fiscal 2013 third quarter ended June 30, 2013.

Fiscal 2013 Third Quarter Highlights

· Revenue of $36.6 million in the third quarter of fiscal 2013

· Goodwill impairment charge of $22.7 million related to the carrying value of the Medical Products business

· Operating loss of $16.8 million includes a goodwill impairment non-cash charge ($22.7 million), IT platform enhancement expense ($1.7 million), and additional customer service support ($0.2 million)

· Net loss of $13.8 million, or $1.46 per diluted share, included a total $2.03 per diluted share of items related to:

o Goodwill impairment charge ($1.88 per share),

o IT platform enhancement expenses ($0.13 per share), and

o Additional customer service support ($0.02 per share).

· Adjusted for goodwill impairment, net income of $4.0 million

· Adjusted EBITDA of $11.1 million

· Updated Financial Guidance:

o Revenue reaffirmed at a range of $150 million to $155 million

o Adjusted EBITDA lowered to a range of $47 million to $49 million

o Net Income range lowered to a range of $18.5 million to $20.5 million, excluding goodwill impairment charge.

· Anticipate restructuring charges of $0.7 million in the fourth quarter of fiscal 2013 associated with a global optimization initiative within the Radiation Measurement business, generating operating expense reductions of approximately $1.3 million annually.

· Extended our $175 million Credit Facility maturity date through July 2018, obtained more flexible covenants, and reduced overall cost of borrowing with lower credit spreads.

- more -

“Our Radiation Measurement and Medical Physics segments are performing as we had planned at their respective operating income levels when guidance for FY 2013 was originally communicated last November, but unplanned market challenges in our Medical Products business have caused us to take an impairment charge and lower EBITDA and net income guidance for FY 2013,” stated Bill Saxelby, President and CEO of Landauer.

“The core Radiation Measurement business continues to perform in line with our expectations for FY 2013 and we are taking steps to improve global efficiency and reduce costs which are a byproduct of creating the management structure around this segment announced in FY 2012. These changes are primarily affecting our European operations. The operating margin performance in our Medical Physics business reflects the positive momentum generated by our profitability improvement initiatives over the last several quarters, and we see increased interest from large hospital systems regarding our enterprise wide radiation safety solution driving opportunities for future growth. In the Medical Products business the new management team’s leadership and direction, sales structure changes and product development efforts have begun to show results in an improved revenue run rate, a significantly improved revenue pipeline for the business, and new business development opportunities. Despite the disappointing year to date results for this business, we are confident that we have the right team and strategy in place to drive profitable growth long-term in this high margin consumable segment.”

“We have taken proactive steps to improve the performance of our traditional Radiation Measurement business and Medical Physics businesses while addressing the competitive sales environment in our Medical Products business. Our focus will continue to be on generating free cash flow to invest in future growth opportunities and maintaining robust dividend distributions to our shareholders,” added Saxelby.

Third Fiscal Quarter Financial Overview and Business Segment Results

Revenues for the third fiscal quarter of 2013 and for the third fiscal quarter of 2012 were $36.6 million and $39.2 million, respectively. The Medical Products segment revenue decreased $1.9 million and revenues in the Radiation Measurement and Medical Physics segments decreased by $0.5 million and $0.2 million, respectively, over the prior fiscal year period. Consolidated revenue for the third fiscal quarter of 2013 was favorably affected in the amount of $0.1 million by currency fluctuation, as compared with the prior fiscal year period, principally due to gains in the Euro against the U.S. dollar.

Gross margins were 50.9 percent for the third fiscal quarter of 2013, compared with 55.7 percent for the third fiscal quarter of 2012. The decrease in the gross margin over the prior year period was due primarily to the impact of the associated reduction in the high gross margin business at our Medical Products, increased depreciation expenses related to the Company’s IT Platform enhancement of $0.5 million as planned, increased IT support services of $0.8 million related to steady state expenses as planned, and increased international costs of $0.2 million, offset by decreased material costs of $0.4 million and decreased service costs of $0.4 million.

Total selling, general and administrative expenses for the third fiscal quarter of 2013 and 2012 were $12.6 million and $12.3 million, respectively. For the third fiscal quarter of 2013, total selling, general and administrative expenses included $0.4 million of additional depreciation expense for the IT platform and $0.2 million of additional customer service support, $0.2 million of increased R&D costs and $0.4 million in other cost increases. Offsetting this was $0.6 million of IT platform enhancement related expense incurred in the prior period and service cost reductions of $0.3 million.

- more -

During the third quarter of 2013, it became apparent that anticipated revenue trends in our Medical Products reporting unit were not being achieved to the extent forecasted. Early budget reviews also indicated future sales growth may be less than expected. We updated the forecasted results of operations for our Medical Products operating segment based on the most recent financial results and our best estimates of future operations. The updated forecast reflects a slower growth in revenues for the Medical Products segment due to anticipated continued pricing pressures from certain competitors greater than the anticipated growth from existing and new product sales. We recorded a $22.7 million pretax charge for the impairment of goodwill to reduce the carrying value of goodwill in our Medical Products segment. The impairment charge is non-cash in nature and does not affect the Company’s liquidity or debt covenant compliance.

Operating loss for the third fiscal quarter of 2013 was $16.8 million, a decrease of $26.0 million, compared with operating income of $9.2 million for the third fiscal quarter of 2012. Operating income, adjusted for the goodwill impairment charge for the third fiscal quarter of 2013, was $6.9 million.

The effective tax rate for the third fiscal quarter of 2013 and 2012 was 21.6% and 23.0%, respectively. The decrease in the effective tax rate was due primarily to benefits from U.S. foreign tax credits. Without impairment of goodwill the effective tax rate would have been 20.9% for the third fiscal quarter of 2013, a decline over the prior year's tax rate due primarily to benefits from U.S. foreign tax credits.

Net loss for the third fiscal quarter ended June 30, 2013 was $13.8 million, or $1.46 per diluted share, compared to net income of $6.6 million, or $0.69 per diluted share, in the same period last year. The decrease in net income was due to a goodwill impairment charge of $22.7 million, reduced high margin Medical Products sales of $1.9 million, increased IT expenses due to the Company’s IT platform enhancement of $1.7 million, additional customer service support of $0.2 million, offset by decreased taxes of $5.8 million, decreased service costs of $0.7 million.

Excluding the costs associated with the goodwill impairment, adjusted net income was $4.0 million. The resulting adjusted diluted earnings per share for the third fiscal quarter ended June 30, 2013 was $0.51 per share.

Adjusted EBITDA for the fiscal third quarter 2013 was $11.1 million compared with $13.9 million for the third fiscal quarter of 2012. The decrease was due primarily to lower earnings. A reconciliation of net income to EBITDA and Adjusted EBITDA is included in the attached financial exhibits.

Radiation Measurement Segment

Radiation Measurement revenues for the third fiscal quarter of 2013 decreased 1.9 percent, or $0.5 million, from the third fiscal quarter of 2012 to $26.4 million. The decrease in the fiscal 2013 third quarter was primarily due to revenue decreases domestically over the prior year third fiscal quarter of $1.2 million, due to fewer equipment sales, offset by international increases of $0.6 million, due to service revenue growth across multiple regions, and currency translation benefits of $0.1 million.

Radiation Measurement operating income for the third fiscal quarter of 2013 decreased to $4.8 million, or 29.4 percent, from $6.8 million in the comparable prior year period. The decrease in operating income was due to increased IT expenses related to the Company’s IT platform enhancement of $1.7 million, $0.5 million decreased revenue, $0.2 million of additional customer service support, $0.2 million of increased R&D, and $0.2 million of international costs, offset by IT platform enhancement expenses of $0.6 million in the prior year period, lower acquisition and restructuring related costs of $0.2 million and lower material costs of $0.2 million.

- more -

Medical Physics Segment

Medical Physics revenues for the third fiscal quarter of 2013 decreased 2.5 percent, or $0.2 million, from the comparable period in fiscal 2012 to $7.9 million. The Medical Physics segment operating income increased to $1.0 million, or 12.7 percent of revenues as compared to operating income of $0.5 million, or 6.2 percent of revenues, in the third fiscal quarter of 2012 due primarily to decreased service costs of $0.7 million. We continue to see opportunity for additional operating improvements as we optimize the utilization model of the business.

Medical Products Segment

Medical Products revenues for the third fiscal quarter of 2013 decreased 45.2 percent, or $1.9 million, from the third fiscal quarter of 2012 to $2.3 million. Medical Products operating loss for the third fiscal quarter of 2013 was $22.6 million as compared to operating income of $1.9 million in the third fiscal quarter of 2012. The decrease in operating income was due primarily to a goodwill impairment of $22.7 million, as well as a decline in selling price and shipments of high margin Spherz product. During the third quarter of 2013, it became apparent that anticipated revenue trends in our Medical Products reporting unit were not being achieved to the extent forecasted. Early budget reviews also indicated future sales growth may be less than expected. We updated the forecasted results of operations for our Medical Products operating segment based on the most recent financial results and our best estimates of future operations. The updated forecast reflects a slower growth in revenues for the Medical Products segment due to anticipated continued pricing pressures from certain competitors greater than the anticipated growth from existing and new product sales. Since achieving a stabilization of revenue trends during the first-half of the fiscal year, we began to experience modest growth during the third fiscal quarter of 2013.

Fiscal Nine Months Financial Overview and Business Segment Results

Revenues for the first nine months of fiscal 2013 were $110.3 million, a decrease of $4.7 million, or 4.1 percent compared with revenues of $115.0 million for the same period in fiscal 2012. The Medical Products segment had a decline of $3.3 million and the Radiation Measurement segment decreased $1.3 million in revenues.

Gross margins were 53.3 percent for the first nine months of fiscal 2013, compared with 58.0 percent for the first nine months of fiscal 2012. The decline in gross margin over the prior year period was due to increased IT expenses related to the Company’s IT Platform enhancement of $3.9 million and international costs of $0.6 million, partially offset by lower materials costs of $1.2 million and lower service costs of $0.2 million.

Total selling, general and administrative expenses for the first nine months of fiscal 2013 were $38.5 million, an increase of $1.3 million, or 3.5 percent, compared to $37.2 million for the first nine months of fiscal 2012. For the first nine months of fiscal 2013, total selling, general and administrative expenses included $1.1 million additional depreciation expense for the IT platform enhancement, $1.0 million of customer service related expenses, other cost changes of $1.0 million and $0.2 million of increased R&D costs, as compared to service cost reductions of $1.0 million and IT platform enhancement related expenses of $1.0 million in the prior year.

In the first nine months of fiscal 2013, we incurred $0.4 million acquisition expenses related primarily to Medical Physics, as compared to $2.5 million in the first nine months of fiscal 2012 primarily due to the acquisition of IZI Medical Products during the first fiscal quarter of 2012.

- more -

Operating loss for the first nine months of fiscal 2013 was $2.9 million, a decrease of $29.9 million, compared with operating income of $27.0 million for the same period in fiscal 2012. The decrease in operating income was due to a goodwill impairment charge of $22.7 million, reduced high margin Medical Products revenue of $3.3 million, reduced Radiation Measurement revenue of $1.3 million, increased IT expenses due to the Company’s IT platform enhancement of $5.0 million and additional customer service support of $1.0 million, compared to acquisition costs of $2.1 million, lower service cost of $1.2 million, material costs of $1.2 million and IT platform enhancement expense of $1.0 million in the prior year period.

The effective tax rate was a benefit of (4.6)% and an expense of 29.2% for the first nine months of fiscal 2013 and 2012, respectively. The decline in the effective tax rate was primarily due to the U.S. research and development credits having a larger impact on our effective tax rate due to lower pretax income. Without impairment of goodwill the effective tax rate would have been 25.7% for the first nine months of fiscal 2013, a decline over the prior year rate due primarily to the U.S. research and development credits.

As a result, net loss for the first nine months of fiscal 2013 of $3.7 million, compared to $18.6 million in the same period in fiscal 2012, primarily due to the goodwill impairment charge of $22.7 million.

Adjusted EBITDA for the first nine months of fiscal 2013 was $35.4 million compared with $42.3 million for the first nine months of fiscal 2012. The decrease was due primarily to lower overall earnings particularly due to reduced high margin Medical Products revenue. A reconciliation of net income to EBITDA and Adjusted EBITDA is included in the attached financial exhibits.

Radiation Measurement Segment

Radiation Measurement revenues for the first nine months of fiscal 2013 decreased 1.6 percent, or $1.3 million, from the first nine months of fiscal 2012 to $80.0 million. The decrease in the first nine months of fiscal 2013 was primarily due to decreases of equipment sales domestically of approximately $2.0 million and currency impacts of $0.2 million, offset by international sales gains of $0.9 million as compared to prior fiscal year first nine months.

Radiation Measurement operating income for the third fiscal quarter of 2013 decreased to $16.1 million, or 22.3 percent, from $21.1 million in the comparable prior year period. The decrease in operating income was due to reduced Radiation Measurement revenue of $1.3 million, increased IT expenses due to the Company’s IT platform enhancement of $5.0 million, additional customer service support of $1.0 million, additional manufacturing and international costs of $0.5 million and $0.2 million of increased R&D costs offset by prior fiscal year first nine months acquisition costs of $2.1 million and prior year IT platform enhancement related costs of $1.0 million.

Medical Physics Segment

Medical Physics revenues for the first nine months of fiscal 2013 decreased $0.1 million from the comparable period in fiscal 2012 to $23.1 million. The Medical Physics segment operating income was $2.6 million, or 11.3 percent of revenues, as compared to $1.5 million, or 6.5 percent of revenues, in the first nine months of fiscal 2012, due primarily to decreased service costs of $1.2 million.

- more -

Medical Products Segment

Medical Products revenues for the first nine months of fiscal 2013 decreased 31.4 percent, or $3.3 million, from the first nine months of fiscal 2012 to $7.2 million. Medical Products operating loss for the first nine months of fiscal 2013 was $21.6 million as compared to $4.3 million in the first nine months of fiscal 2012. The decrease in operating income was due to a goodwill impairment charge of $22.7 million and a decline in revenue by $3.3 million. During the third quarter of 2013, it became apparent that anticipated revenue trends in our Medical Products reporting unit were not being achieved to the extent forecasted. Early budget reviews also indicated future sales growth may be less than expected. We updated the forecasted results of operations for our Medical Products operating segment based on the most recent financial results and our best estimates of future operations. The updated forecast reflects a slower growth in revenues for the Medical Products segment due to anticipated continued pricing pressures from certain competitors greater than the anticipated growth from existing and new product sales.

Balance Sheet

Landauer ended the third fiscal quarter of 2013 with total assets of $270.9 million, compared to total assets of $302.1 million at the end of fiscal 2012, a decrease of $31.2 million, of which $22.7 million was related to the goodwill impairment charge. The Company completed the quarter with $9.0 million of cash and cash equivalents on the balance sheet and unused borrowing capacity of $35.4 million under its newly extended $175 million credit facility, which provides adequate liquidity to meet its current and anticipated obligations. Net operating cash flow generated during the first nine months of fiscal 2013 was $16.5 million. We have amended and extended our credit facility with our lenders to provide increased flexibility under our covenant structure and reduced borrowing spreads, and have extended the term of the maturity date to July 2018.

Fiscal 2013 Outlook

Saxelby concluded, “We have revised our Adjusted EBITDA and Net Income outlook for the remainder of the year driven primarily by the lack of performance of our Medical Products business. Despite having to lower our near-term expectations, we continue to be focused on the long-term growth of the consolidated business and remain committed to executing against our strategic objectives, maintaining a robust dividend and creating value for our shareholders over the long-term.”

Landauer’s business plan for fiscal 2013 currently anticipates aggregate revenues for the year to be in the range of $150 to $155 million. The business plan also anticipates a blended effective tax rate for the full fiscal year to be within a range of 26 percent to 28 percent, excluding any impact due to the goodwill impairment charge.

Based upon the above assumptions, the Company anticipates reported net income for fiscal 2013 in the range of $18.5 to $20.5 million and Adjusted EBITDA expected for fiscal 2013 in the range of $47 to $49 million.

- more -

Conference Call Details

Landauer has scheduled its third quarter conference call for investors over the Internet on Tuesday, August 6, 2013, at 9:00 a.m. Central Time (10 a.m. Eastern Time). To participate, callers should dial 877-941-1465 (within the United States and Canada), or 480-629-9867 (international callers) about 10 minutes before the presentation. To listen to a webcast on the Internet, please go to the Company’s website at http://www.landauer.com at least 15 minutes early to register, download and install any necessary audio software.  Investors may access a replay of the call by dialing 800-406-7325 (within the United States and Canada), or 303-590-3030 (international callers), passcode 4631429#, which will be available through Friday, September 6, 2013. The replay will also be available on Landauer’s website for 90 days following the call.

About Landauer

Landauer is a leading global provider of technical and analytical services to determine occupational and environmental radiation exposure, the leading domestic provider of outsourced medical physics services, as well as a provider of high quality medical accessories used in radiology, radiation therapy, and image guided surgery procedures. For more than 50 years, the Company has provided complete radiation dosimetry services to hospitals, medical and dental offices, universities, national laboratories, nuclear facilities and other industries in which radiation poses a potential threat to employees. Landauer’s services include the manufacture of various types of radiation detection monitors, the distribution and collection of the monitors to and from customers, and the analysis and reporting of exposure findings. The Company provides its dosimetry services to approximately 1.8 million individuals globally. In addition, through its Medical Physics segment, the Company provides therapeutic and imaging physics services to the medical physics community. Through its Medical Products segment, the Company provides medical consumable accessories used in radiology, radiation therapy, and image guided surgery procedures. For information about Landauer, please visit our website at http://www.landauer.com.

- more -

Safe Harbor Statement

Some of the information shared here (including, in particular, the section titled “Fiscal 2013 Outlook”) constitutes forward-looking statements that are based on assumptions and involve certain risks and uncertainties. These include the following, without limitation: assumptions, risks and uncertainties associated with the Company’s future performance, the Company’s development and introduction of new technologies in general; the ability to protect and utilize the Company’s intellectual property; continued customer acceptance of the InLight technology; the adaptability of optically stimulated luminescence (OSL) technology to new platforms and formats; military and other government funding for the purchase of certain of the Company’s equipment and services; the impact on sales and pricing of certain customer group purchasing arrangements; changes in spending or reimbursement for medical products or services; the costs associated with the Company’s research and business development efforts; the usefulness of older technologies and related licenses and intellectual property; the effectiveness of and costs associated with the Company’s IT platform enhancements; the anticipated results of operations of the Company and its subsidiaries or ventures; valuation of the Company’s long-lived assets or business units relative to future cash flows; changes in pricing of services and products ; changes in postal and delivery practices; the Company’s business plans; anticipated revenue and cost growth; the ability to integrate the operations of acquired businesses and to realize the expected benefits of acquisitions; the risks associated with conducting business internationally; costs incurred for potential acquisitions or similar transactions; other anticipated financial events; the effects of changing economic and competitive conditions, including instability in capital markets which could impact availability of short and long-term financing; the timing and extent of changes in interest rates; the level of borrowings; foreign exchange rates; government regulations; accreditation requirements; changes in the trading market that affect the costs of obligations under the Company’s benefit plans; and pending accounting pronouncements. These assumptions may not materialize to the extent assumed, and risks and uncertainties may cause actual results to be different from what is anticipated today. These risks and uncertainties also may result in changes to the Company’s business plans and prospects, and could create the need from time to time to write down the value of assets or otherwise cause the Company to incur unanticipated expenses. Additional information may be obtained by reviewing the information set forth in Item 1A “Risk Factors” and Item 7A “Quantitative and Qualitative Disclosures about Market Risk” and information contained in the Company's Annual Report on Form 10-K for the year ended September 30, 2012 and other reports filed by the Company, from time to time, with the Securities and Exchange Commission. The Company does not undertake, and expressly disclaims, any duty to update any forward-looking statement whether as a result of new information, future events or changes in the Company’s expectations, except as required by law.

During the past several years, the Company has been engaged in an initiative to re-engineer many of its business processes and replace significant components of its information technology systems. A principal component of this initiative is the implementation of new enterprise resource planning software and other applications to manage certain business operations. This enhancement of the Company’s IT platform has been a complex project and has involved extensive customization of the Company’s software and IT systems. In July 2012, the enhanced IT platform became operational. Although the Company has been encouraged by its experience with the enhanced platform during the first several months of the platform’s start-up phase, there can be no assurance that the new platform will continue to maintain its functionality at the levels anticipated or otherwise meet the Company’s business and operational objectives. If unforeseen problems arise, the Company’s operations could be adversely impacted, including the ability of the Company to perform one or more of the following in a timely manner: customer quotes, customer orders, product shipment, customer services and support, order billing and tracking, contractual obligations fulfillment and related operations. As previously disclosed, the Company expects to incur ongoing maintenance expenditures for the new IT platform at levels higher than the Company traditionally experienced under its prior platform. Unforeseen problems with the new platform could increase further such expenditures.

Financial Tables Follow

- more -

Landauer, Inc. and Subsidiaries

Consolidated Balance Sheets

(Dollars in Thousands)	June 30, 2013		September 30, 2012
ASSETS
Current assets:
Cash and cash equivalents	$	8,997	$	17,633
Receivables, net of allowances of $728 and $1,088, respectively		34,807		35,165
Inventories		9,487		8,638
Prepaid income taxes		3,513		2,148
Prepaid expenses and other current assets		4,518		3,975
Current assets		61,322		67,559
Property, plant and equipment, at cost		106,248		101,375
Accumulated depreciation and amortization		(53,326)		(46,983)
Net property, plant and equipment		52,922		54,392
Equity in joint ventures		22,735		24,108
Goodwill		83,833		106,717
Intangible assets, net of accumulated amortization of $12,229 and $9,696, respectively		37,987		37,402
Dosimetry devices, net of accumulated depreciation of $9,989 and $8,879, respectively		6,221		6,189
Other assets		5,837		5,758
Assets	$	270,857	$	302,125
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable	$	5,490	$	9,656
Dividends payable		5,389		5,345
Deferred contract revenue		13,572		14,947
Accrued compensation and related costs		7,146		8,260
Other accrued expenses		8,863		7,096
Current liabilities		40,460		45,304
Non-current liabilities:
Long-term debt		139,560		141,347
Pension and postretirement obligations		17,655		17,586
Deferred income taxes		10,118		15,733
Other non-current liabilities		892		1,053
Non-current liabilities		168,225		175,719
Stockholders' equity:
Preferred stock, $.10 par value per share, authorized 1,000,000 shares; none issued		0		0
Common stock, $.10 par value per share, authorized 20,000,000 shares; 9,589,705 and 9,493,368 shares issued and outstanding at June 30, 2013 and September 30, 2012 respectively		959		949
Additional paid in capital		39,034		35,898
Accumulated other comprehensive loss		(7,866)		(5,272)
Retained earnings		28,721		48,142
Landauer, Inc. stockholders' equity		60,848		79,717
Noncontrolling interest		1,324		1,385
Stockholders' equity		62,172		81,102
Liabilities and Stockholders' Equity	$	270,857	$	302,125

- more -

Landauer, Inc. and Subsidiaries

Third Fiscal Quarter 2013 Financial Highlights

		Three Months Ended June 30,				Nine Months Ended June 30,
(Dollars in Thousands, Except per Share)		2013		2012		2013		2012
Net revenues	$	36,580	$	39,205	$	110,343	$	114,968
Cost and expenses:
Cost of sales		17,964		17,357		51,577		48,292
Selling, general and administrative		12,550		12,251		38,519		37,216
Goodwill impairment charge		22,700		0		22,700		0
Acquisition and reorganization costs		142		348		442		2,509
Costs and expenses		53,356		29,956		113,238		88,017
Operating (loss) income		(16,776)		9,249		(2,895)		26,951
Equity in income of joint ventures		471		684		2,555		2,555
Interest expense, net		(1,154)		(1,113)		(3,268)		(2,566)
Other income (expense), net		112		(50)		431		0
(Loss) income before taxes		(17,347)		8,770		(3,177)		26,940
Income taxes		(3,748)		2,014		146		7,860
Net (loss) income		(13,599)		6,756		(3,323)		19,080
Less:  Net income attributed to noncontrolling interest		154		190		400		479
Net (loss) income attributed to Landauer, Inc.	$	(13,753)	$	6,566	$	(3,723)	$	18,601
Net (loss) income per share attributable to Landauer, Inc. shareholders:
Basic	$	(1.46)	$	0.70	$	(0.40)	$	1.98
Weighted average basic shares outstanding		9,439		9,371		9,402		9,357
Diluted	$	(1.46)	$	0.69	$	(0.40)	$	1.97
Weighted average diluted shares outstanding		9,439		9,412		9,402		9,397
Dividends paid per share	$	0.55	$	0.55	$	1.65	$	1.65

- more -

A reconciliation of these non-GAAP measures to the most directly comparable GAAP measures is provided below:

	Three Months Ended June 30,
	2013		2012
Adjusted EBITDA
Net (loss) income attributed to Landauer, Inc.	$	(13,753)	$	6,566
Add back:
Interest expense, net		1,049		1,020
Depreciation and amortization		3,884		2,722
Provision for income taxes		(3,748)		2,014
(Loss) earnings before interest, taxes, depreciation and amortization (EBITDA)	$	(12,568)	$	12,322
Adjustments:
Non-cash stock based compensation		789		661
IT platform enhancements expenses		1		585
Acquisition and reorganization costs		142		348
Goodwill impairment charge		22,700		0
Sub-total adjustments		23,632		1,594
Adjusted EBITDA	$	11,064	$	13,916
Adjusted Net Income
Net (loss) income attributed to Landauer, Inc.	$	(13,753)	$	6,566
Sub-total adjustments		23,632		1,594
Income-taxes on adjustments		(5,105)		(367)
Adjustments, net		18,527		1,227
Adjusted, Net Income	$	4,774	$	7,793
Adjusted Net Income per Diluted Share	$	0.51	$	0.83

- more -

	Nine Months Ended June 30,
	2013		2012
Adjusted EBITDA
Net (loss) income attributed to Landauer, Inc.	$	(3,723)	$	18,601
Add back:
Interest expense, net		2,957		2,319
Depreciation and amortization		10,860		7,752
Provision for income taxes		146		7,860
Earnings before interest, taxes, depreciation and amortization (EBITDA)	$	10,240	$	36,532
Adjustments:
Non-cash stock-based compensation expense		1,855		2,115
IT platform enhancements expenses		206		1,173
Acquisition and reorganization costs		442		2,509
Goodwill impairment charge		22,700		0
Sub-total adjustments		25,203		5,797
Adjusted EBITDA	$	35,443	$	42,329
Adjusted Net Income
Net (loss) income attributed to Landauer, Inc.	$	(3,723)	$	18,601
Sub-total adjustments		25,203		5,797
Income taxes on adjustments		1,159		(1,693)
Adjustments, net		26,362		4,104
Adjusted Net Income	$	22,639	$	22,705
Adjusted Net Income per Diluted Share	$	2.41	$	2.42
Free Cash Flow
Net cash provided by operating activities	$	16,533	$	30,453
Capital expenditures		(5,286)		(11,476)
Free Cash Flow		11,247		18,977
IT platform enhancements expenses		206		1,173
Acquisition and reorganization costs		442		2,509
Adjusted Free Cash Flow	$	11,895	$	22,659

- more -

Segment Information

Three Months Ended June 30, 2013
	Radiation Measurement		Medical Physics		Medical Products		Consolidated
Revenues	$	26,383	$	7,903	$	2,294	$	36,580
Operating income (loss)		4,759		1,056		(22,591)		(16,776)
Three Months Ended June 30, 2012
	Radiation Measurement		Medical Physics		Medical Products		Consolidated
Revenues	$	26,926	$	8,064	$	4,215	$	39,205
Operating income		6,813		517		1,919		9,249
Nine Months Ended June 30, 2013
	Radiation Measurement		Medical Physics		Medical Products		Consolidated
Revenues	$	80,035	$	23,090	$	7,218	$	110,343
Operating income (loss)		16,142		2,580		(21,617)		(2,895)
Nine Months Ended June 30, 2012
	Radiation Measurement		Medical Physics		Medical Products		Consolidated
Revenues	$	81,328	$	23,186	$	10,454	$	114,968
Operating income		21,132		1,519		4,300		26,951

	June 30, 2013		September 30, 2012
Segment assets:
Radiation Measurement	$	163,001	$	171,831
Medical Physics		35,784		36,304
Medical Products		72,072		93,990
Consolidated assets	$	270,857	$	302,125

- # # # -

EX-99.2

Exhibit 99.2

Investor Slide Presentation

Respect Innovation Honesty Reliability Investor Presentation August 2013

2 Safe Harbor Statement Some of the information shared here (including, in particular, the section titled “Fiscal 2013 Outlook”) constitutes forward - looking statements that are based on assumptions and involve certain risks and uncertainties . These include the following, without limitation : assumptions, risks and uncertainties associated with the Company’s future performance, the Company’s development and introduction of new technologies in general ; the ability to protect and utilize the Company’s intellectual property ; continued customer acceptance of the InLight technology ; the adaptability of optically stimulated luminescence (OSL) technology to new platforms and formats ; military and other government funding for the purchase of certain of the Company’s equipment and services ; the impact on sales and pricing of certain customer group purchasing arrangements ; changes in spending or reimbursement for medical products or services ; the costs associated with the Company’s research and business development efforts ; the usefulness of older technologies and related licenses and intellectual property ; the effectiveness of and costs associated with the Company’s IT platform enhancements ; the anticipated results of operations of the Company and its subsidiaries or ventures ; valuation of the Company’s long - lived assets or business units relative to future cash flows ; changes in pricing of products and services ; changes in postal and delivery practices ; the Company’s business plans ; anticipated revenue and cost growth ; the ability to integrate the operations of acquired businesses and to realize the expected benefits of acquisitions ; the risks associated with conducting business internationally ; costs incurred for potential acquisitions or similar transactions ; other anticipated financial events ; the effects of changing economic and competitive conditions, including instability in capital markets which could impact availability of short and long - term financing ; the timing and extent of changes in interest rates ; the level of borrowings ; foreign exchange rates ; government regulations ; accreditation requirements ; changes in the trading market that affect the costs of obligations under the Company’s benefit plans ; and pending accounting pronouncements . These assumptions may not materialize to the extent assumed, and risks and uncertainties may cause actual results to be different from what is anticipated today . These risks and uncertainties also may result in changes to the Company’s business plans and prospects, and could create the need from time to time to write down the value of assets or otherwise cause the Company to incur unanticipated expenses . Additional information may be obtained by reviewing the information set forth in Item 1 A “Risk Factors” and Item 7 A “Quantitative and Qualitative Disclosures about Market Risk” and information contained in the Company's Annual Report on Form 10 - K for the year ended September 30 , 2012 and other reports filed by the Company, from time to time, with the Securities and Exchange Commission . The Company does not undertake, and expressly disclaims, any duty to update any forward - looking statement whether as a result of new information, future events or changes in the Company’s expectations, except as required by law . During the past several years, the Company has been engaged in an initiative to re - engineer many of its business processes and replace significant components of its information technology systems . A principal component of this initiative is the implementation of new enterprise resource planning software and other applications to manage certain business operations . This enhancement of the Company’s IT platform has been a complex project and has involved extensive customization of the Company’s software and IT systems . In July 2012 , the enhanced IT platform became operational . Although the Company has been encouraged by its experience with the enhanced platform during the first several months of the platform’s start - up phase, there can be no assurance that the new platform will continue to maintain its functionality at the levels anticipated or otherwise meet the Company’s business and operational objectives . If unforeseen problems arise, the Company’s operations could be adversely impacted, including the ability of the Company to perform one or more of the following in a timely manner : customer quotes, customer orders, product shipment, customer services and support, order billing and tracking, contractual obligations fulfillment and related operations . As previously disclosed, the Company expects to incur ongoing maintenance expenditures for the new IT platform at levels higher than the Company traditionally experienced under its prior platform . Unforeseen problems with the new platform could increase further such expenditures .

Financial Highlights Three Operating Segments Diverse Markets Served Business Facts Business Facts • Based in Glenwood, IL • Founded in 1954 • Approximately 550 employees • Global Platform and Infrastructure • 78,000 annual customers served; 1.7 annual individuals served • 94%+ Customer retention rates Three Operating Segments • Radiation Measurement • 77% of FY 2012 Op Income • Medical Physics • 10% of FY 2012 Op Income • Medical Products • 13% of FY 2012 Op Income Financial Highlights Diverse Markets Served The Global Leader in Radiation Science and Services Landauer Today 3 • $160 Million in Annual Revenue (Fiscal 2012) • ~ 90% Recurring Revenues • 21+ consecutive years of revenue growth • $55 Million in Adjusted EBITDA (Fiscal 2012) • $165 Million in Cumulative Dividends paid over last 10 years $ • Healthcare & Education • National Security • Energy • Industry

Radiation Management is Becoming More Complex Advanced imaging and treatment choices, healthcare consolidation and tougher regulations and standards are raising the bar for radiation safety Evolving Treatments Advanced radiation treatment choices and consumerism Healthcare Consolidation Acquisitions Partnerships Tougher State and Federal Regulations Regulatory Trends • CT, PA, MA, RI, TX New Standards Patient Safety and National Public Policy Risk to Health System 4

Radiation Risk Not Managed Consistently Healthcare Systems do not have a single expert focused on radiation risk across all locations, departments and modalities • Radiation injury and even death • Lawsuits $100K - $15M+ • Violations, delays in patient care, & poor PR • Risk to pregnant & at - risk patients • Excess exposure to staff • Radiation injury and death • Lawsuits $200K - $17M+ • Reportable events to state DOH, TJC, FDA • Delays in patient care or even ceased operations • All impact regulatory compliance & employee safety • Violations • Delays in patient care • Poor PR • Gaps in radiation safety training • Dosimeters not worn or returned • Lack of meaningful exposure review and follow up • No documentation that radiation levels in public areas are safe • Outdated radiological emergency plans • Incomplete or unknown patient dose benchmarking & CT protocol review • Failure of state, NRC, & TJC inspections • Outdated or non - standardized policy and procedures • Casual or absent privileging for fluoroscopy operators • Radiation over/under – dose, imprecise delivery or unintended exposure due to improper equipment calibration or lock of QA/QC • Lack of checklists, training, oversight • Regulatory non - compliance Medical Imaging Risks Radiation Oncology Risks Employee Monitoring Risks 5

Building an Integrated Radiation Safety Solution Occupational Monitoring/Patient Monitoring Market Opportunity: $ 365M “ Dose to Worker ” Radiation Measurement Market Share Leader/Stable Business Market Share Leader/Fragmented Competition Adjacent Product Segment/High Margin Consumables Core Business Complementary Acquisitions Imaging Physics/Therapy Physics Market Opportunity: $1B “Dose to Patient” Therapy/Diagnostic Accessories Market Opportunity: $200M “Dose Accuracy” The Only Enterprise - Wide Radiation Safety Solution Provider Medical Physics Medical Products 6

Attractive Niche Business Model – Annuity Focused Hospitals Nuclear Power Medical Imaging Industry Radiation Measurement Therapy Imaging Commissioning Medical Physics Image Guided Procedures Radiation Therapy Medical Products Strong, Stable Core Business with Growth Opportunities Complementary Growth Businesses 77% of LDR’s Operating Income 23% of LDR’s Operating Income 7 90 % Annuity Service 10% Equipment 90% Annuity Service 10% Episodic 100% Consumables

* Note: Fiscal 2009 Net Income excludes $1.8M after - tax impact of charges Driving Strong Cash Flows… Revenue, Net Income & Cash Flow from Operations ($ in Millions) 8 75.2 79.0 82.1 90.0 93.8 114.4 120.5 152.4 19 20 21 23 25* 24 25 19 21 24 28 35 31 26 31 36 28% 30% 34% 39% 33% 23% 26% 24% 0% 10% 20% 30% 40% 50% $0M $20M $40M $60M $80M $100M $120M $140M $160M $180M $200M 2005 2006 2007 2008 2009 2010 2011 2012 Revenue Net Income Cash Flow % Revenue Net Income Cash Flow Margin

…and Generating Robust Dividend Payments “Best In Class” Dividend Yield 0.0% 0.5% 1.0% 1.5% 2.0% 2.5% 3.0% 3.5% 4.0% 4.5% 5.0% $0.60 $0.80 $1.00 $1.20 $1.40 $1.60 $1.80 $2.00 $2.20 $2.40 Sep - 03 Sep - 04 Sep - 05 Sep - 06 Sep - 07 Sep - 08 Sep - 09 Sep - 10 Sep - 11 Sep - 12 Annual Dividend Per Share Annual Dividend per Share Avg Dividend Yield 9

Executing a Successful Strategy Optimize Core Competitive Growth Strategic Expansion Deliver Sustainable Long Term Growth and Maximize Total Shareholder Returns 10

Radiation Measurement Strategic Initiatives □ Management/Structure • New Segment President Q3 FY 2012 □ IT Platform Enhancement • Went live in July 2012 • Order to Cash Functionality • Full System Functionality, Declining Stabilization Expenses □ Global Shared Services • Sales/Marketing • Manufacturing/Operations • Finance/Human Resources 2012 Revenue: $108M 2012 Operating Income: $21.5M □ International Expansion • $11M in 2005; $30M in 2012 • 11 Countries in 2005; 44 countries in 2012 □ New Channels/Existing Technologies • Military, First Responder • $23+ million new orders □ New Products/Existing Technology • Patient Monitoring □ Informatics Expansion • Leverage dose history information for 1.6 million participants □ Business Development • Assessing Global Opportunities □ New Technology/New Products • Next Generation Dosimetry Platform Investments Radiation Measurement Strategic Expansion Competitive Growth Optimize the Core 11

Medical Physics Strategic Initiatives □ Management/Structure • New Segment President Q4 FY 2012 □ Profitability Improvement Initiatives • Operating Loss (FY 2010 & 2011) • Operating Income FY 12: 6.5% of Revenues • Operating Income: - YTD FY13: 11.3% of Revenues - Q3 FY13: 12.7% of Revenues □ Hospital Group Purchasing Interest • FY 2011 to Current □ Hospital Group Purchasing Contract Negotiations • Enterprise Wide Radiation Safety Solution • 2 GPOs/4000 Hospitals • Contract Decisions Q3 & Q4 FY 2013 □ Bayer Dose to Patient Software Collaboration • FY 2013 Partnership • Low Dose Consultation Offering □ Business Development • Practice Group Acquisitions • Tied to Enterprise Wide Radiation Safety Solution • Currently evaluating several key geographic market opportunities 2012 Revenue : $ 31M 2012 Operating Income : $1.3M Medical Physics 12 Strategic Expansion Competitive Growth Optimize the Core

Medical Products Strategic Initiatives □ Management/Structure • New Segment President Q1 FY 2013 • GM and Product Development Experience • J&J, Baxter, and Cardinal • New VP of Sales 2Q’13 • Med Device exp. • Telesales exp. – 7 yrs • New Senior VP of Business Development • Former Precino Med President • Former IZI Sales/Marketing Exec • 10 years of image guided industry experience □ Revenue Pipeline Expansion • $7M currently □ New Product Introduction • New Spherz initiative – Q4 FY 2013 □ New Strategic Initiatives • Radiation Therapy Product Additions • Centers of Excellence Established • Group Purchasing Agreements Added □ Business Development • Assessing companies/new technologies □ Acquired Assets of Precino Med • Completed in Q2 FY 2013 2012 Revenue: $13.5M 2012 Operating Income: $5.3M Medical Products 13 Strategic Expansion Competitive Growth Optimize the Core

Q3 FY 2013 Highlights Radiation Measurement ▪ Top Line Initiatives ▪ Bottom Line Initiatives Strategic Expansion • Patient monitoring – new Microstar system introduction in Q4 FY 2013 • Next generation dosimetry platform – R&D development Competitive Growth • Group purchasing changing dynamics • Radwatch military sales of $3.0M since Q2 FY 2013 Optimize the Core • IT system stabilization • More than 8,500 customers on new system/ 3,000 on legacy system • Globalization/Shared Services Efficiency Medical Physics • Strategic acquisitions represent new revenue opportunities – tied to integrated delivery networks • Currently assessing multiple acquisitions • Hospital group purchasing contract negotiations – 2 GPOs/4000 hospitals • Enterprise wide radiation safety solution presented to largest US GPO • Optimize personnel utilization • Exit low margin legacy contracts • 11.3% operating margin YTD‘13, compared to 6.7% in FY ‘12 Medical Products • Acquired assets of Precino Med • Focus on image - guided surgery, radiation therapy and advanced medical imaging • Focus on $7M pipeline execution • New Spherz initiative - Q4 FY 2013 • New senior leadership team installed 14

Q3 FY 2013 Highlights Innovative New Products Radwatch “Cloud based Data Management” http:// youtube/ETsvfary6m0 Radiation Measurement 15 MicroStar 2 “Patient Dose Data Management”

Financial Overview Respect Innovation Honesty Reliability

Landauer Financial Overview ($ in millions, FYE 9/30) Revenue $93.8 $114.4 $120.5 $ 152.4 $ 152.5* 2009 2010 2011 2012 2013E ($ in millions, FYE 9/30) Adjusted EBITDA $45.3 $46.6 $ 48.5 $54.2 $48* 2009 2010 2011 2012 2013E ▪ Approximately 90 % of revenue derived from subscription and is recurring in nature ▪ Core business growing organically in the 3 % to 5 % range going forward ▪ Contract with U . S . military to replace its antiquated radiation monitoring system provides opportunities to expand to other global military and first responder markets ▪ Strategic expansion contributing to long term growth prospects ▪ Strong history of EBITDA to support dividend return to shareholders, reinvestment in the core business and capital required to support strategic expansion ▪ 27 % growth in revenue and 12 % growth in EBITDA in FY 2012 reflecting execution of business strategy * Midpoint of guidance (8/6) 17

3Q’ FY13 Financial Highlights Adjusted EBITDA ▪ Revenue of $ 36 . 6 million in the third quarter of fiscal 2013 ▪ Goodwill impairment charge of $ 22 . 7 million related to the carrying value of the Medical Products business ▪ Operating loss of $ 16 . 8 million includes goodwill impairment charge ( $ 22 . 7 million ), IT platform enhancement expense ( $ 1 . 7 million), and additional customer service support ( $ 0 . 2 million ), versus prior year period . Adjusted Operating income for non - cash impairment : $ 6 . 9 million . ▪ Net loss of $ 13 . 8 million, or $ 1 . 46 loss per diluted share, included goodwill impairment charge ( $ 1 . 88 per share), IT platform enhancement expenses ( $ 0 . 13 per share), and additional customer service support ( $ 0 . 02 per share ), versus prior year period . Adjusted Net Income for non - cash impairment : $ 4 . 0 million . ▪ Adjusted EBITDA of $ 11 . 1 million ▪ Anticipate restructuring charges of approximately $ 0 . 7 million in the fourth quarter of fiscal 2013 associated with a global optimization initiative within the Radiation Measurement business, generating operating expense reductions of approximately $ 1 . 3 million annually $26 $80 $8 $23 $2 $7 $ 152.5* $0 $50 $100 $150 $200 Q3 2012 YTD FY 2013 Estimate Thousands Radiation Measurement Medical Physics $11 $35 $48* $0 $10 $20 $30 $40 $50 $60 Q3 2012 YTD FY 2013 Estimate Thousands Revenue 18 * Midpoint of guidance (8/6)

FY 2013 Outlook vs. FY 2012 Actual Fiscal Year 2013 Outlook - Updated ▪ Expected Revenue $150 to $155 million, which includes a full year of contributions from IZI Medical Products acquisition, versus 10.5 months in fiscal 2012 ▪ Adjusted EBITDA of $47 to $49 million ▪ Net Income of $18.5 to $ 20.5 million, not including impact of impairment charge Outlook ▪ New IT Platform Enhancement: $ 4.3 million incremental (Non - cash $2.4 million) ▪ Non - cash Stock Based Compensation Expense: $ 0.2 million incremental ▪ Impact from reduced high margin IZI revenue 19

20 Dividend Policy ▪ Board of Directors declared a regular quarterly cash dividend of $0.55 per share for the third quarter of fiscal 2013 – This represents an annual rate of $2.20 per share, consistent with fiscal 2013 levels – For the t hird fiscal quarter, the dividend was paid on July 3 , 2013 to shareholders of record on June 7, 2013 Recent Dividend Payment

Appendix Respect Innovation Honesty Reliability

Landauer, Inc. is a recognized leader in personal and environmental radiation measurement and monitoring, outsourced medical physics services and high - quality medical consumable accessories LDR Corporate Evolution InLight product technology released Acquired IZI Medical Products: Genesis of Medical Products Segment Estimated Revenues of $150M to $155M for FY’13 • Adjusted EBITDA of $51M to $53M • Net Income of $21M to $23M Raised annual dividend rate from $2.15 to $2.20 Acquired Global Physics Solutions: Genesis of Medical Physics Segment First launch of RadWatch solution Bill Saxelby named President and CEO Reported FY’06 Revenue of $79M • Initiated global IT Systems overhaul • Replaced 35 year old IBM Mainframe • Michael Burke appointed to CFO • Greg Groenke appointed Pres / GM IZI Medical Products • Mike Kaminski appointed Pres / GM Radiation Measurement • Systems Initiative Phase 3.0 Completed • Successful System Launch $ 22 2005 2009 2010 2011 2012 2013 2006 2007 2008

23 New IT Platform Enhancement Expenses  Depreciation / Steady State / Customer Service / Implementation / Stabilization expenses: ― Total FY 2013 vs. FY 2012 $ 4.3 million increased expense over prior year (previously $4.4 million) • Depreciation, additional $2.4 million » Split between COG’s ($1.4 million) and SG&A ($1.0 million ) • Ongoing Steady State expense, additional $2.9 million (previously $3.0 million) • Customer Service Support expense, additional $0.9 million; declines over time • FY 2012 Implementation expense ($1.2 million) – eliminated in FY 2013 • Non - recurring stabilization expense, lower by $0.8 million FY 2013 Outlook vs. FY 2012 Actual Actual Actual FY 2013 Estimate Q1 Actual Q2 Actual Q3 Actual 2011 2012 2013 2013 2013 Implementation Expense $1,185 $1,172 - - - - Depreciation $1,005 $1,914 $4,351 $1,048 $1,095 $ 1,096 Customer Service - - $891 $512 $313 $198 Comet Steady State - - $2,915 $463 $997 $899 Comet Stabilization Expense - $983 $207 $178 $27 - Total $2,190 $4,069 $8,364 $2,201 $2,432 $ 2,193 (in thousands)

• Customer Records - o ver 500M records migrated from IBM legacy system to new IT System platform • LDR Data Center Co - location Strategy – Phase 1.0 (FY12), Phase 2.0 (FY13). Disaster Recovery / • Redundancy / Risk Mitigation: total investment to date $3.4M • Landauer Databases – over 325% increase in databases supported: 75  325 • Landauer Application Servers - 450 % growth in servers: 45  250 • MyLDR.com - 9,000+ Customers vs. 3000 Customers on IBM legacy systems • RadWatch Military / Emergency Response Software - enabled $7.1M revenue achievement in FY12 • MicroStar Software Platform – over 400 Customers supported since 2007. Enabled $9M one - time revenue, and $500K recurring revenue since 2011; new microSTARii launched Q4, FY13 • Independent Laboratory Systems – 15 Global Customer installations / infrastructure support since April, 2009 • RadWizard Data Management System – Over 600 Customers / over 150K participants monitored • Customer Facing Solutions – 45 developed since 2007 • Application Portfolio – over 300 different application solutions supported: customers & internal solutions LDR IT Evolution: 2006 - 2013 Applications (since 2007) Infrastructure (since 2007) 2003 Luxel + Technology introduced 2005 InLight Product Technology released 2007 • COMET Program started • 229 Applications Supported 20 10 • Nagase Landauer online w/ ILS • COMET Phase 1 Finance released 20 09 • First ILS Software Solution Developed • SIS and RadWizard released to market 20 11 • COMET Phase 2.0 myLDR.com 1.0 • RadWizard 2.0 20 12 • COMET Phase 3.0, myLDR.com 2.0 • RadWizard 3.0 • Landauer Data Center Phase 1.0 Landauer I/T Org: Basis of Support 24 20 13 • Landauer Data Center Phase 2.0